© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
February 26th 2024
AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
February 23rd 2024
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
February 23rd 2024
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.
New Research Highlights Specific Allergens that May Predispose Sensitized Children with Asthma to Upper Respiratory Infections
February 22nd 2024
AAAAI 2024. Indoor mouse and cockroach, but not cat and dog, allergen exposure were associated with URI outcomes among children with asthma.
New neffy Data on Clinical Efficacy Presented at 2024 AAAAI Annual Meeting
February 22nd 2024
AAAAI 2024. New data on neffy (epinephrine nasal spray) include the first report of efficacy after oral food challenge in a pediatric population at risk for anaphylaxis.
Dupilumab Plus Medium-Dose Inhaled Corticosteroid Improved Lung Function and Asthma Control, According to New Data
February 21st 2024
AAAAI 2024. Patients with asthma who received dupilumab plus medium-dose ICS had improved lung function and asthma control vs those who received placebo plus high-dose ICS.
Dupilumab Effective Up to 5 Years in Adults with Moderate-to-Severe Atopic Dermatitis in Open-Label Extension Study
February 21st 2024
AAAAI 2024. Reduction of AD signs and symptoms was significant among approximately half of study participants at 4 weeks and continuously rose through week 260, investigators report.
First Study of Oral Mucosal Immunotherapy for Peanut Allergy Elicits Robust Immunologic Response in Adults
February 21st 2024
AAAAI 2024. Oral mucosal immunotherapy delivered via metered-dose toothpaste produced a statistically significant increase in IgG4 and a decrease in IgE/IgG4 ratio.
Tezepelumab Demonstrates Sustained Post-Treatment Reductions in CSU Disease Activity, Inflammatory Markers
February 21st 2024
AAAAI 2024. The effects, seen 18 to 20 weeks after discontinuation of tezepelumab, suggest a persistent effect of thymic stromal lymphopoietin (TSLP) blockade in CSU.
More Timely Care for Chronic Liver Disease is Coming, Step-by-Step, says Hepatologist Bruce Luxon, MD, PhD
December 4th 2023
Reducing stigma associated with chronic liver disease and expediting diagnosis and referral will take some time but progress is being made, Luxon says.